Αim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function.
Eighty five sexually active women suffering from overactive bladder were prospectively enrolled in this study. Females were divided into two groups. In Group A (control), 48 patients received no treatment and in Group B, 37 patients received mirabegron 50 mg/daily for 3 months. Patients were evaluated with FSFI-Gr at the beginning of the study and again after a period of 3 months.
In Group B, there was a significant increase post-treatment compared to baseline (p < 0.001) in total FSFI (20.3 (3.8) to 26.6 (4.2)) and all domains (desire: 3.0 (1.2) to 4.8 (1.2)), arousal: 3.0 (0.8) to 4.8 (0.9), lubrication: 3.9 (1.1) to 4.8 (1.2), orgasm: 3.6 (0.8) to 4.8 (1.0), satisfaction: 3.2 (0.4) to 4.0 (0.8) and pain: 3.2 (0.8) to 4.4 (1.2)). In Group A, there were no statistically significant changes in pre- and post-observation values.
This study is one of the few demonstrating that management of OAB with mirabegron improves female sexual function.
TRN ISRCTN17199301 , 20/10/2017, retrospectively registered.
BMC urology. 2018 Jun 25*** epublish ***
A Zachariou, C Mamoulakis, M Filiponi, F Dimitriadis, J Giannakis, S Skouros, P Tsounapi, A Takenaka, N Sofikitis
Department of Urology, School of Medicine, Ioannina University, Ioannina, Greece. ., Department of Urology, University General Hospital of Heraklion, University of Crete, Medical School, Heraklion, Greece., Department of Urology, ELPIS Hospital, Volos, Greece., Department of Urology, School of Medicine, Ioannina University, Ioannina, Greece., Department of Urology, School of Medicine, Tottori University, Yonago, Japan.